Table of Contents Table of Contents
Previous Page  21 / 168 Next Page
Information
Show Menu
Previous Page 21 / 168 Next Page
Page Background

2

I

GROUP ACTIVITY FOR THE FINANCIAL YEAR AND OUTLOOK FOR THE COMING YEAR

2.1

I

LISI CONSOLIDATED

At €1,643.4million consolidated sales for the 2017 financial year were up

4.6% and include the following items:

■■

a scope effect of €21.7 million corresponding to:

a negative impact of -€13.4 million or 0.8% of consolidated sales

revenues that reflects the sale of Précimétal Fonderie de Précision

(Belgium) on February 2, 2017,

theincrementalcontributionbyLISIMEDICALRemmele(consolidated

as of May 1, 2016) for €22.8 million, i.e. 1.4% of the consolidated sales

revenue,

€12.3 million (0.75% of consolidated sales revenue) contributed by

the integrationwithin LISI AUTOMOTIVE of theUS company TERMAX,

a leading designer and manufacturer of metal and plastic fastening

solutions for the automotive industry, effective November 1, 2017;

■■

a negative currency effect of €10.2million;

■■

€60.8 million generated by organic growth.

Comments regarding business

€ million

LISI Consolidated

of which

LISI AEROSPACE

of which

LISI AUTOMOTIVE

of which

LISI MEDICAL

Q1

444.3

277.6

128.9

37.9

Q2

417.4

258.3

123.7

35.6

Organic growth H1 2017/H1 2016

+ 6.1%

+ 7.4%

+ 3.7%

+ 7.1%

Q3

369.7

222.6

116.2

31.1

Q4

412.0

242.4

137.3

32.5

Organic growth H2 2017/H2 2016

+ 1.0%

- 1.1%

+ 9.6%

- 8.6%

2017

1,643.4

1,000.9

506.0

137.0

Expressed at constant scope and exchange rates, the change in sales

revenues was +3.6% (+4.6% in 2016).

Analysis by half-year

Organic growth slowed in the second half of the year (+1.0%) after steady

growth in the first half (+6.1%), especially in the LISI AEROSPACE and

LISI MEDICAL divisions. Trends in the LISI AUTOMOTIVE division are

favorable.

Analysis by quarter

Compared with the same period last year, the fourth quarter posted

overall organic growth of +2.8% and was mainly driven by “Structural

Components” activity in the aerospace sector and the entire

LISI AUTOMOTIVE division. The “Fasteners” activities in Aerospace and

the Medical Division showed no sign of improvement over the fourth

quarter of the previous year.

Analysis by division

On a like-for-like basis and restated for foreign exchange effects,

LISI AEROSPACE’s consolidated annual sales revenues increased 3.3%

andexceededonebillioneurosforthefirsttime in itshistory.Thedivision

experienced a decline in the second half of the year (-1.1%) compared to

the first (+7.4%). The “Fasteners” activity in Europe suffered not only

from the negative effect of the Airbus inventory reductions, but also

the accelerated depreciation of the US dollar against the euro. In the

United States, “Fasteners” activity picked up steam at Boeing, while the

active repositioning of LISI AEROSPACEwith the distribution sector was

hampered by low activity levels for business and regional aircraft. The

“Structural Components” activity had good momentum throughout the

year, thanks in particular to the continued ramp-up of new programs,

including the LEAP engine.

The LISI AUTOMOTIVE division experienced an acceleration in sales

between the first and second half of the year (+3.6% in H1, +9.6% in H2)

in a European market that remains solid. The increase in sales revenue

is particularly significant in the Clipped Solutions and the Safety

Mechanical Components segments, resulting in gains in market shares

and the ramp-up of new products. As a result, sales revenues reached

thehistorical levelof€506.0million,up8.8%comparedto2016,with6.5%

organic growth supported by high order intake for new projects of over

10%of sales revenue.

The LISI MEDICAL division benefited from the full-year effect of the

integration of LISI MEDICAL Remmele (incremental sales revenue of

€22.8 million over the period). At constant scope and exchange rates,

sales decreased by 2.3% with the second half-year clearly showing a

decrease (-8.6%) comparedwith the first (+7.1%). LISI MEDICAL Remmele

had to cope with a temporary delay in the ramping-up of some of its

products in for minimally invasive surgeries and also saw two significant

products reassigned to other production processes.

21

LISI 2017 FINANCIAL REPORT

FINANCIAL SITUATION

2